NeuroMetrix (NURO) 10-Q 23 Apr 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 22, 2020
Document And Entity Information [Abstract]
Substantial Doubt about Going Concern, within One Year [true false]	true
Entity Registrant Name	NeuroMetrix, Inc.
Entity File Number	001-33351
Entity Tax Identification Number	043308180
Entity Address, Address Line One	4B Gill Street
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01801
City Area Code	781
Local Phone Number	890-9989
Entity Central Index Key	0001289850
Trading Symbol	NURO
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,736,207
Class of Warrant or Right, Outstanding		41,627

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,816,485	$ 3,126,206
Accounts receivable, net	386,124	298,967
Inventories	1,153,560	1,163,714
Collaborator Payments Receivable	181,330	189,008
Prepaid expenses and other current assets	340,369	652,919
Total current assets	4,877,868	5,430,814
Fixed assets, net	250,041	273,448
Operating Lease, Right-of-Use Asset	1,048,937	1,159,774
Other long-term assets	29,650	29,650
Total assets	6,206,496	6,893,686
Current liabilities:
Accounts payable	623,193	725,658
Accrued expenses	1,064,580	1,443,574
Accrued Sales Return provisions	603,000	689,000
Operating Lease, Liability, Current	591,370	588,546
Total current liabilities	2,882,143	3,446,778
Operating Lease, Liability, Noncurrent	810,235	916,674
Total liabilities	3,692,378	4,363,452
Commitments and contingencies
Stockholders’ equity:
Preferred stock	1	1
Common stock, $0.0001 par value; 100,000,000 shares authorized at June 30, 2019 and December 31, 2018; 9,781,755 and 7,380,463 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	168	140
Additional paid-in capital	197,960,925	197,319,698
Accumulated deficit	(195,446,976)	(194,789,605)
Total stockholders’ equity	2,514,118	2,530,234
Total liabilities and stockholders’ equity	6,206,496	6,893,686
Non-Convertible Preferred Stock
Stockholders’ equity:
Preferred stock	0	0
Convertible preferred stock
Stockholders’ equity:
Total stockholders’ equity	$ 1	$ 1

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Shares, Outstanding	1,687,752	1,400,674
Common Stock, Shares, Issued	1,687,752	1,400,674
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 2,172,036	$ 3,122,935
Other Income	498	16,813
Other Nonoperating Income	498	5,751,662
Net income (loss)	(657,371)	2,050,507
Loss from operations	(657,869)	(3,701,155)
Collaboration Income	0	5,734,849
Net income (loss) applicable to common stockholders:
Net income (loss) applicable to common stockholders	$ (657,371)	$ 2,050,507
Earnings Per Share, Basic	$ (0.45)	$ 2.65
Earnings Per Share, Diluted	$ (0.45)	$ 1.47
Weighted Average Number of Shares Outstanding, Basic	1,457,224	774,146
Operating expenses:
Research and development	$ 533,620	$ 855,081
Sales and marketing	424,349	2,025,288
General and administrative	1,251,746	1,619,490
Total operating expenses	2,209,715	4,499,859
Gross profit	1,551,846	798,704
Cost of revenues	$ 620,190	$ 2,324,231

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		15 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (657,371)	$ 2,050,507
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	23,407	31,778
Stock-based compensation	144,047	44,093
CompensationObligationSettlement	43,751	0
IdleFacilityImpairmentCharge	87,000	0	$ 487,000
Inventory Write-down	0	700,000
Changes in operating assets and liabilities:
Accounts receivable	(87,157)	110,605
Inventories	10,154	(182,404)
Increase (Decrease) In Collaboration Receivable	7,678	0
Prepaid expenses and other current and long-term assets	312,550	(101,579)
Accounts payable	(102,465)	(740,223)
Accrued expenses	(458,772)	657,059
Increase (Decrease) in Accrued Product Returns	(86,000)	(374,766)
Increase (Decrease) in Deferred Collaboration Income	0	(1,774,704)
Net Cash Provided by (Used in) Operating Activities	(763,178)	420,366
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	453,457	0
Net Cash Provided by (Used in) Financing Activities	453,457	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(309,721)	420,366
Cash and cash equivalents, end of period	2,816,485		2,816,485
Supplemental disclosure of cash flow information:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	2,816,485	7,200,795	$ 2,816,485	$ 3,126,206	$ 6,780,429
Stock Issuance Settle Incentive Compensation Obligation	$ 43,751	$ 0

Equity Rollforward Statement

Equity Rollforward Statement - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Stockholders' Equity Attributable to Parent	$ 6,097,811	$ 18	$ 74	$ 197,114,310	$ (191,016,591)
Shares, Outstanding		17,813.63	738,029
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	44,093			44,093
Conversion of Stock, Shares Converted		(2,445.90)
Conversion of Stock, Amount Converted		$ (3)		(6)
Stock Issued During Period, Shares, Conversion of Convertible Securities			(93,000)
Stock Issued During Period, Value, Conversion of Convertible Securities			$ (9)
Net Income (Loss) Attributable to Parent	2,050,507				2,050,507
Stockholders' Equity Attributable to Parent	8,192,411	$ 15	$ 83	197,158,397	(188,966,084)
Shares, Outstanding		15,367.73	831,029
Stockholders' Equity Attributable to Parent	2,530,234	$ 1	$ 140	197,319,698	(194,789,605)
Shares, Outstanding		200	1,400,674
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	144,047			144,047
Stock Issued During Period, Shares, New Issues			256,078
Stock Issued During Period, Value, New Issues	453,457		$ 25	453,432
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture			31,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	43,751		$ 3	43,748
Net Income (Loss) Attributable to Parent	(657,371)				(657,371)
Stockholders' Equity Attributable to Parent	$ 2,514,118	$ 1	$ 168	$ 197,960,925	$ (195,446,976)
Shares, Outstanding		200	1,687,752

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc., or the Company, is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE ™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell ® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available OTC. The Company maintains an active, industry-leading R&D program. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has reported recurring losses from operations and negative cash flows from operating activities. At March 31, 2020 , the Company had an accumulated deficit of $195.4 million . These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period from the date of issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company held cash and cash equivalents of $2.8 million as of March 31, 2020 . The Company believes that these resources and the cash to be generated from future product sales will be sufficient to meet its projected operating requirements into the first quarter of 2021. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the first quarter of 2021 and beyond. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products, including related to the COVID-19 pandemic, and the uncertainty of future revenues from new products; (b) the effect of the COVID-19 pandemic on the Company's ability to obtain parts and materials from the Company's suppliers while continuing to staff critical production and fulfillment functions; (c) changes the Company may make to the business that affect ongoing operating expenses; (d) changes the Company may make in its business strategy; (e) regulatory developments affecting the Company’s existing products; (f) changes the Company may make in its research and development spending plans; and (g) other items affecting the Company’s forecasted level of expenditures and use of cash resources. The Company may attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such funding in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2020 , unaudited statements of operations, changes in stockholders' equity and cash flows for the quarters ended March 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2019 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2020 (File No. 001-33351), or the Company’s 2019 Form 10-K. Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded net of the allowance for doubtful accounts, which represents the Company’s best estimate of credit losses. Allowance for doubtful accounts was $70,000 as of March 31, 2020 and December 31, 2019 . Two customers accounted for 36% of total revenues in the quarter ended March 31, 2020 . Two customers accounted for 32% of total revenues in the quarter ended March 31, 2019. Three customers accounted for 62% and two customers accounted for 42% of accounts receivable as of March 31, 2020 and December 31, 2019 , respectively. Collaboration income Collaboration income is recognized within Other income when contractual performance obligations, outside the ordinary activities of the Company, have been satisfied and control has been transferred to a collaboration partner. Collaboration income for each performance obligation is based on the fair value of such performance obligation relative to the total fair value of all performance obligations multiplied by the overall transaction price. A deferred collaboration income liability is recorded when payments are received prior to satisfaction of performance obligations. A collaboration receivable is recorded when amounts are owed to the Company under the collaboration agreements and related support services. The Company recognized Collaboration income net of costs, within Other income in the Statement of Operations of zero and $5,734,849 , for the quarters ended March 31, 2020 and 2019, respectively. Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2020 was $408,144 . The total compensation costs are expected to be recognized over a weighted-average period of 0.8 years. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Comprehensive Loss

Comprehensive Loss	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Comprehensive Loss	Comprehensive Income (Loss) For the quarters ended March 31, 2020 and 2019 , the Company had no components of other comprehensive income (loss) other than net income (loss) itself.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Common Share	3. Net (Loss) Income Per Common Share Basic and dilutive net income (loss) per common share were as follows: Quarters Ended March 31, 2020 2019 Net income (loss) applicable to common stockholders $ (657,371 ) $ 2,050,507 Weighted average number of common shares outstanding, basic 1,457,224 774,146 Dilutive convertible preferred stock — 622,720 Weighted average number of common shares outstanding, dilutive 1,457,224 1,396,866 Net income (loss) per common share applicable to common stockholders, basic $ (0.45 ) $ 2.65 Net income (loss) per common share applicable to common stockholders, diluted $ (0.45 ) $ 1.47 Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net income (loss) per common share because their effect was anti-dilutive for each of the periods presented: Quarters Ended March 31, 2020 2019 Options 164,091 48,849 Warrants 42,086 45,937 Convertible preferred stock 62 — Total 206,239 94,786
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2020 2019 Net income (loss) applicable to common stockholders $ (657,371 ) $ 2,050,507 Weighted average number of common shares outstanding, basic 1,457,224 774,146 Dilutive convertible preferred stock — 622,720 Weighted average number of common shares outstanding, dilutive 1,457,224 1,396,866 Net income (loss) per common share applicable to common stockholders, basic $ (0.45 ) $ 2.65 Net income (loss) per common share applicable to common stockholders, diluted $ (0.45 ) $ 1.47

Inventories

Inventories	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: March 31, 2020 December 31, 2019 Purchased components $ 736,791 $ 720,209 Finished goods 416,769 443,505 $ 1,153,560 $ 1,163,714

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses and Compensation Accrued expenses and compensation consist of the following: March 31, 2020 December 31, 2019 Technology fees $ 450,000 $ 450,000 Professional services 292,000 454,000 Compensation 92,758 62,322 Advertising and promotion 60,000 68,000 Warranty 63,700 75,300 Other 106,122 333,952 $ 1,064,580 $ 1,443,574

Leases Leases (Notes)

Leases Leases (Notes)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lessee, Operating Leases [Text Block]	Operating Leases The Company's lease on its Woburn, Massachusetts facilities (the “Woburn Lease”) extends through September 2025 with a monthly base rent of $13,846 and a 5 -year extension option. The Company's lease on its Waltham, Massachusetts facilities, now inactive and offered for sublet, extends through February 2022 with an average monthly base rent of $41,074 and a 5 -year extension option. At March 31, 2020, the Company recorded an impairment reserve of $487,000 that reduced the right of use asset for Waltham idle facility costs. Future minimum lease payments under non-cancellable operating leases as of March 31, 2020 are as follows: 2020 482,391 2021 653,164 2022 247,347 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 1,831,903 Weighted-average discount rate, 14.7% $ 430,298 Lease obligation, current portion 591,370 Lease obligation, net of current portion 810,235 $ 1,831,903 Total recorded rent expense was $166,904 and $166,024 , for the quarters ended March 31, 2020 and 2019, respectively. The Company records rent expense on its facility leases on a straight-line basis over the lease term. Weighted average remaining operating lease term was 3.4 years as of March 31, 2020.

Restructuring And Related Activ

Restructuring And Related Activities (Notes)	3 Months Ended
	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The obligations relating to the business restructuring outstanding as of March 31, 2020 are presented below. March 31, 2020 Severance obligations: Provision $ 224,773 Amounts paid out (224,773 ) Total — Relocation costs: Provision 100,000 Amounts paid out (100,000 ) Total — Impairment charge for idle facility 487,000 Amounts paid out (87,000 ) Total 400,000 Balance - March 31, 2020 $ 400,000
Restructuring and Related Activities Disclosure [Text Block]	Business Restructuring In the second quarter of 2019, the Company was restructured to reduce operating costs and improve efficiency. Operations were consolidated in a single location, headcount was reduced, and excess inventory was written down to net realizable value. The total 2019 restructuring charge was $2.3 million . The total impairment charge in the first quarter of 2020 was $87,000 . The Company's Waltham facility was idled and as of March 31, 2020 had not been sublet, and a reserve of $487,000 was recorded against the Company's right to use for this asset. The obligations relating to the business restructuring outstanding as of March 31, 2020 are presented below. March 31, 2020 Severance obligations: Provision $ 224,773 Amounts paid out (224,773 ) Total — Relocation costs: Provision 100,000 Amounts paid out (100,000 ) Total — Impairment charge for idle facility 487,000 Amounts paid out (87,000 ) Total 400,000 Balance - March 31, 2020 $ 400,000

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Fair Value Measurements at March 31, 2020 Using March 31, 2020 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 12 $ 12 $ — $ — Total $ 12 $ 12 $ — $ — Fair Value Measurements at December 31, 2019 Using December 31, 2019 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 698,807 $ 698,807 $ — $ — Total $ 698,807 $ 698,807 $ — $ —

Credit Facility

Credit Facility	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Credit Facility	Credit Facility The Company is party to a Loan and Security Agreement, as amended (the “Credit Facility”), with a bank. As of March 31, 2020 , the Credit Facility permitted the Company to borrow up to $250,000 on a revolving basis. The Credit Facility was amended most recently on January 23, 2020 and extended until April 30, 2020 . Amounts borrowed under the Credit Facility will bear interest equal to the prime rate plus 0.5% . Any borrowings under the Credit Facility will be collateralized by the Company’s cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by the Company. As of March 31, 2020 , the Company was in compliance with these covenants and had not borrowed any funds under the Credit Facility. However, $226,731 of the amount under the Credit Facility is restricted to support letters of credit issued in favor of the Company's landlords. Consequently, the amount available for borrowing under the Credit Facility as of March 31, 2020 was approximately $23,269 .

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Preferred stock and convertible preferred stock	Preferred stock and convertible preferred stock consist of the following: March 31, 2020 December 31, 2019 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2020 and December 31, 2019; 200 shares issued and outstanding at March 31, 2020 and December 31, 2019 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ —
Stockholders' Equity	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2020 December 31, 2019 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2020 and December 31, 2019; 200 shares issued and outstanding at March 31, 2020 and December 31, 2019 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — 2020 equity activity In February 2020, the Company entered into an At Market Issuance Sales Agreement (the "Agreement") with respect to an at-the-market offering program ("ATM program"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $2,200,000 (the "Placement Shares"). The issuance and sale, if any, of the Placement Shares by the Company under the Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the three months ended March 31, 2020, 256,078 shares of common stock were issued pursuant to the Agreement for proceeds of $453,457 . In March 2020, the Company issued 31,000 shares of fully vested common stock with a value of $43,751 pursuant to a Separation Agreement between the Company and an employee. The shares issued reflected the $1.41 closing price of the Company's common stock as reported on the Nasdaq Capital Market on March 11, 2020. 2019 equity activity During the three months ended March 31, 2019 , 526 shares of the Company's Series D Preferred Stock were converted into a total of 20,000 shares of Common Stock and 1,919.90 shares of the Company's Series E Preferred Stock were converted into a total of 73,000 shares of Common Stock. On November 18, 2019, the Company effected a 1-for-10 reverse stock split of its Common Stock, or the Reverse Stock Split. The par value and other terms of the common stock were not affected by the Reverse Stock Split. Share, per share, and stock option amounts for all periods presented within the financial statements contained in the Quarterly Report on Form 10-Q, including the December 31, 2019 Balance Sheet amounts for Common Stock and additional paid-in capital, have been retroactively adjusted to reflect the Reverse Stock Split.

Reverse Stock Split

Reverse Stock Split	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Reverse Stock Split	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2020 December 31, 2019 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2020 and December 31, 2019; 200 shares issued and outstanding at March 31, 2020 and December 31, 2019 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019 $ — $ — 2020 equity activity In February 2020, the Company entered into an At Market Issuance Sales Agreement (the "Agreement") with respect to an at-the-market offering program ("ATM program"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $2,200,000 (the "Placement Shares"). The issuance and sale, if any, of the Placement Shares by the Company under the Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the three months ended March 31, 2020, 256,078 shares of common stock were issued pursuant to the Agreement for proceeds of $453,457 . In March 2020, the Company issued 31,000 shares of fully vested common stock with a value of $43,751 pursuant to a Separation Agreement between the Company and an employee. The shares issued reflected the $1.41 closing price of the Company's common stock as reported on the Nasdaq Capital Market on March 11, 2020. 2019 equity activity During the three months ended March 31, 2019 , 526 shares of the Company's Series D Preferred Stock were converted into a total of 20,000 shares of Common Stock and 1,919.90 shares of the Company's Series E Preferred Stock were converted into a total of 73,000 shares of Common Stock. On November 18, 2019, the Company effected a 1-for-10 reverse stock split of its Common Stock, or the Reverse Stock Split. The par value and other terms of the common stock were not affected by the Reverse Stock Split. Share, per share, and stock option amounts for all periods presented within the financial statements contained in the Quarterly Report on Form 10-Q, including the December 31, 2019 Balance Sheet amounts for Common Stock and additional paid-in capital, have been retroactively adjusted to reflect the Reverse Stock Split.

Commitments And Contingencies C

Commitments And Contingencies Commitments And Contingencies (Notes)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies [Abstract]
Commitments and Contingencies Disclosure [Text Block]	The previously reported investigation by the Federal Trade Commission (the “Commission”) regarding compliance of the Company’s representations about its Quell® product with Sections 5 and 12 of the Federal Trade Commission Act was settled in March 2020. The defendants, Dr. Shai Gozani, NeuroMetrix, Inc. President and Chief Executive Officer, and the Company, did not admit any of the allegations in the Commission’s proposed complaint. In the settlement, Dr. Gozani and the Company have agreed to certain modifications of Quell advertising claims. Further, the Commission was paid Four Million Dollars ( $4,000,000 ) by Dr. Gozani, and the Company pledged to pay to the Commission future commercial milestone payments, if and when received, pursuant to a collaboration agreement with a third party. The settlement has been entered by the United States District Court for the District of Massachusetts.

Subsequent Event Subsequent Eve

Subsequent Event Subsequent Event	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	From April 1, 2020 to April 16, 2020, the Company issued 1,048,455 shares of common stock under its ATM program. Net proceeds from this activity was $1,680,356 .

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Share-based Payment Arrangement [Policy Text Block]	Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2020 was $408,144 . The total compensation costs are expected to be recognized over a weighted-average period of 0.8 years.
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2020 , unaudited statements of operations, changes in stockholders' equity and cash flows for the quarters ended March 31, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2019 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 28, 2020 (File No. 001-33351), or the Company’s 2019 Form 10-K.
Revenues	Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded net of the allowance for doubtful accounts, which represents the Company’s best estimate of credit losses. Allowance for doubtful accounts was $70,000 as of March 31, 2020 and December 31, 2019 . Two customers accounted for 36% of total revenues in the quarter ended March 31, 2020 . Two customers accounted for 32% of total revenues in the quarter ended March 31, 2019. Three customers accounted for 62% and two customers accounted for 42% of accounts receivable as of March 31, 2020 and December 31, 2019 , respectively. Collaboration income Collaboration income is recognized within Other income when contractual performance obligations, outside the ordinary activities of the Company, have been satisfied and control has been transferred to a collaboration partner. Collaboration income for each performance obligation is based on the fair value of such performance obligation relative to the total fair value of all performance obligations multiplied by the overall transaction price. A deferred collaboration income liability is recorded when payments are received prior to satisfaction of performance obligations. A collaboration receivable is recorded when amounts are owed to the Company under the collaboration agreements and related support services. The Company recognized Collaboration income net of costs, within Other income in the Statement of Operations of zero and $5,734,849 , for the quarters ended March 31, 2020 and 2019, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2020 2019 Net income (loss) applicable to common stockholders $ (657,371 ) $ 2,050,507 Weighted average number of common shares outstanding, basic 1,457,224 774,146 Dilutive convertible preferred stock — 622,720 Weighted average number of common shares outstanding, dilutive 1,457,224 1,396,866 Net income (loss) per common share applicable to common stockholders, basic $ (0.45 ) $ 2.65 Net income (loss) per common share applicable to common stockholders, diluted $ (0.45 ) $ 1.47
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Quarters Ended March 31, 2020 2019 Options 164,091 48,849 Warrants 42,086 45,937 Convertible preferred stock 62 — Total 206,239 94,786

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: March 31, 2020 December 31, 2019 Purchased components $ 736,791 $ 720,209 Finished goods 416,769 443,505 $ 1,153,560 $ 1,163,714

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and compensation consist of the following: March 31, 2020 December 31, 2019 Technology fees $ 450,000 $ 450,000 Professional services 292,000 454,000 Compensation 92,758 62,322 Advertising and promotion 60,000 68,000 Warranty 63,700 75,300 Other 106,122 333,952 $ 1,064,580 $ 1,443,574

Leases Leases (Tables)

Leases Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 482,391 2021 653,164 2022 247,347 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 1,831,903 Weighted-average discount rate, 14.7% $ 430,298 Lease obligation, current portion 591,370 Lease obligation, net of current portion 810,235 $ 1,831,903

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Fair Value Measurements at March 31, 2020 Using March 31, 2020 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 12 $ 12 $ — $ — Total $ 12 $ 12 $ — $ — Fair Value Measurements at December 31, 2019 Using December 31, 2019 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 698,807 $ 698,807 $ — $ — Total $ 698,807 $ 698,807 $ — $ —

Business and Basis of Present_3

Business and Basis of Presentation (Detail)	Nov. 18, 2019	Mar. 31, 2020USD ($)$ / shares	Mar. 31, 2019USD ($)$ / shares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Organization And Basis Of Presentation [Line Items]
Restructuring Charges				$ 2,300,000
Accounts receivable, net		$ 386,124		298,967
Net proceeds from issuance of stock and warrants		453,457	$ 0
Accumulated deficit		195,446,976		194,789,605
Cash and cash equivalents		2,816,485		3,126,206
Allowance for doubtful accounts		70,000		70,000
Reverse stock split conversion ratio	0.1
Prepaid expenses and other current assets		(340,369)		(652,919)
Assets, Current		(4,877,868)		(5,430,814)
Accrued Sales Return provisions		603,000		689,000
Liabilities, Current		(2,882,143)		(3,446,778)
Operating Lease, Liability, Noncurrent		(810,235)		(916,674)
Stockholders' Equity Attributable to Parent		2,514,118	8,192,411	2,530,234	$ 6,097,811
Cost of revenues		620,190	2,324,231
Gross Profit		1,551,846	798,704
Net Income (Loss) Available to Common Stockholders, Diluted		(657,371)	$ 2,050,507
Compensation cost not yet recognized		$ 408,144
Compensation cost not yet recognized, period for recognition		9 months 18 days
Earnings Per Share, Basic | $ / shares		$ (0.45)	$ 2.65
Earnings Per Share, Diluted | $ / shares		$ (0.45)	$ 1.47
Operating Lease, Right-of-Use Asset		$ (1,048,937)		(1,159,774)
Other long-term assets		(29,650)		(29,650)
Assets		(6,206,496)		(6,893,686)
Accrued Liabilities, Current		(1,064,580)		(1,443,574)
Liabilities		(3,692,378)		$ (4,363,452)
Collaboration Income		$ 0	$ 5,734,849
Two Customers | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage		36.00%	32.00%
Two Customers | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage				42.00%
Three Customers | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage		62.00%

Comprehensive Loss (Detail)

Comprehensive Loss (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Equity [Abstract]
Other comprehensive income (loss), net of tax	$ 0	$ 0

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	206,239	94,786
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	62	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	42,086	45,937
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	164,091	48,849

Net Loss Per Common Share Sched

Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Income (Loss) Available to Common Stockholders, Diluted	$ (657,371)	$ 2,050,507
Weighted Average Number of Shares Outstanding, Basic	1,457,224	774,146
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock	0	622,720
Weighted Average Number of Shares Outstanding, Diluted	1,457,224	1,396,866
Earnings Per Share, Basic	$ (0.45)	$ 2.65
Earnings Per Share, Diluted	$ (0.45)	$ 1.47

Inventories (Detail)

Inventories (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Inventory [Line Items]
Purchased components	$ 736,791		$ 720,209
Inventory Write-down	0	$ (700,000)
Finished goods	416,769		443,505
Inventories	$ 1,153,560		$ 1,163,714

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Sales return allowance	$ 603,000	$ 689,000
Technology fees	450,000	450,000
Professional services	292,000	454,000
Warranty reserve	63,700	75,300
Accrued Advertising	60,000	68,000
Accrued Salaries	92,758	62,322
Other	106,122	333,952
Accrued expenses	$ 1,064,580	$ 1,443,574

Leases Leases (Details)

Leases Leases (Details) - USD ($)	Jun. 01, 2018	Feb. 20, 2015	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Operating Leased Assets [Line Items]
Operating Lease, Weighted Average Discount Rate, Percent			15.00%
Operating Lease, Weighted Average Remaining Lease Term			3 years 4 months 24 days
Operating Leases, Rent Expense			$ 166,904	$ 166,024
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months			482,391
Lessee, Operating Lease, Liability, Payments, Due Year Two			653,164
Lessee, Operating Lease, Liability, Payments, Due Year Three			247,347
Lessee, Operating Lease, Liability, Payments, Due Year Four			165,785
Lessee, Operating Lease, Liability, Payments, Due Year Five			165,785
Lessee, Operating Lease, Liability, Payments, Due after Year Five			117,431
Lessee, Operating Lease, Liability, Payments, Due			1,831,903
Operating Lease Discount			430,298
Operating Lease, Liability, Current			591,370		$ 588,546
Operating Lease, Liability, Noncurrent			$ 810,235		$ 916,674
Woburn Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Lease Expiration Date			Sep. 30, 2025
Woburn Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments	$ 13,846
Waltham Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term		5 years
Lease Expiration Date			Feb. 28, 2022
Waltham Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments		$ 41,074

Restructuring And Related Act_2

Restructuring And Related Activities (Details) - USD ($)	3 Months Ended		12 Months Ended	15 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 2,300,000
Severance Costs			224,773
Restructuring Reserve	$ 400,000			$ 400,000
IdleFacilityImpairmentCharge	87,000	$ 0		487,000
Facility Relocation Costs			100,000
Inventory Write-down	0	$ 700,000
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring			(224,773)
Restructuring Reserve	0			0
Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring			$ (100,000)
Restructuring Reserve	0			0
Idle Facility Impairment [Member]
Restructuring Cost and Reserve [Line Items]
Payments for Restructuring	(87,000)
Restructuring Reserve	$ 400,000			$ 400,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Assets
Cash equivalents	$ 12	$ 698,807
Assets, Fair Value Disclosure	12	698,807
Level 1
Assets
Cash equivalents	12	698,807
Assets, Fair Value Disclosure	12	698,807
Level 2
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	0	0
Level 3
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	$ 0	$ 0

Credit Facility (Detail)

Credit Facility (Detail) - USD ($)	Jan. 23, 2020	Mar. 31, 2020
Line of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity		$ 250,000
Credit facility expiration date	Apr. 30, 2020
Credit facility limit restricted to support letter of credit		226,731
Line of credit facility, remaining borrowing capacity		$ 0
Prime Rate
Line of Credit Facility [Line Items]
Interest rate over prime rate		0.50%

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock and Convertible Preferred Stock (Detail) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Value of preferred stock issued	$ 1	$ 1
Non-Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 1	$ 1
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	200	200
Preferred stock, shares outstanding (in shares)	200	200
Preferred stock, shares designated (in shares)	147,000	147,000
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares designated (in shares)	21,300	21,300
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares designated (in shares)	7,000	7,000
Series F Convertible Preferred Stock
Class of Stock [Line Items]
Value of preferred stock issued	$ 0	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares designated (in shares)	10,621	10,621

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 11, 2020	Feb. 29, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Net proceeds from issuance of stock and warrants	$ 453,457	$ 0
Common stock, par value (in dollars per share)	$ 0.0001				$ 0.0001
Common Stock, Shares, Issued	1,687,752				1,400,674
Common Stock, Value, Issued	$ 168				$ 140
Compensation cost not yet recognized	$ 408,144
Compensation cost not yet recognized, period for recognition	9 months 18 days
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)	0				0
Conversion of Stock, Shares Converted		526
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)	0				0
Conversion of Stock, Shares Converted		(1,919.9)
Common Stock [Member] | Series D Convertible Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)		(20,000)
Common Stock [Member] | Series E Convertible Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion (in shares)		(73,000)
Separation Agreement [Member]
Class of Stock [Line Items]
Stock Price (in dollars per share)			$ 1.41
Common Stock, Shares, Issued	31,000
Common Stock, Value, Issued	$ 43,751
At The Market Offering Program [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)				$ 0.0001
Maximum Aggregate Offering Price				$ 2,200,000
Common Stock, Shares, Issued	256,078
Proceeds from Issuance of Common Stock	$ 453,457

Reverse Stock Split (Details)

Reverse Stock Split (Details)	Nov. 18, 2019	Mar. 31, 2020shares	Dec. 31, 2019shares
Class of Stock [Line Items]
Shares outstanding (in shares)		1,687,752	1,400,674
Reverse stock split conversion ratio	0.1

Commitments And Contingencies_2

Commitments And Contingencies Commitments And Contingencies (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Commitments and Contingencies [Abstract]
Payments for Legal Settlements	$ 4,000,000

Subsequent Event Subsequent E_2

Subsequent Event Subsequent Events (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 16, 2020	Mar. 31, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Common Stock, Shares, Issued		1,687,752	1,400,674
At The Market Offering Program [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued		256,078
Proceeds from Issuance of Common Stock		$ 453,457
At The Market Offering Program [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	1,048,455
Proceeds from Issuance of Common Stock	$ 1,680,356